Literature DB >> 9830591

Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre.

S R Thomas1, K M Gyi, H Gaya, M E Hodson.   

Abstract

In many patient populations there has been a progressive increase in the prevalence of methicillin-resistant Staphylococcus aureus (MRSA). We examined the prevalence and consequences of acquiring MRSA in the adult cystic fibrosis (CF) population at Royal Brompton. Patients who became colonized by MRSA between 1965 and 1997 were identified from an existing database and case-notes were reviewed. Clinical and microbiological data were recorded. Twenty-six patients became colonized with MRSA during this period. Median age at acquisition was 23.4 years (range 11.8-43.3 years) and median FEV1 (percent predicted) was 28.9% (range 12-81%). Twenty patients (77%) had an FEV1 of < or = 40% predicted MRSA was probably acquired by four patients at Royal Brompton. In 17 patients isolates wer first identified whilst under the care of a total of 11 other institutions. Since the first case of MRSA infection in 1982, there has been an increase in prevalence to a current rate of nine cases in the first seven months of 1997. The commonest site of colonization was the lower airway (96%); the nose (23%) and skin sites (15%) were more rarely affected. Duration of colonization was frequently brief with nine cases (35%) lasting less than one month. The identification of MRSA appeared to be of little clinical significance, and did not generally affect outcomes. Only three patients were MRSA positive at the time of death, and in only one of these was MRSA considered a possible contributing factor.

Entities:  

Mesh:

Year:  1998        PMID: 9830591     DOI: 10.1016/s0195-6701(98)90138-4

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  8 in total

Review 1.  Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.

Authors:  Andrew M Jones; A Kevin Webb
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis.

Authors:  L S Miall; N T McGinley; K G Brownlee; S P Conway
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

4.  Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients.

Authors:  V Cafiso; T Bertuccio; D Spina; F Campanile; D Bongiorno; M Santagati; A Sciacca; C Sciuto; S Stefani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-04       Impact factor: 3.267

Review 5.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

6.  Linezolid pharmacokinetics in adult patients with cystic fibrosis.

Authors:  John A Bosso; Patrick A Flume; Susan L Gray
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

7.  MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.

Authors:  Emilie Vallières; Jacqueline C Rendall; John E Moore; John McCaughan; Anne I Hoeritzauer; Michael M Tunney; Joseph Stuart Elborn; Damian G Downey
Journal:  ERJ Open Res       Date:  2016-03-15

Review 8.  Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis.

Authors:  Susanna Esposito; Guido Pennoni; Valeria Mencarini; Nicola Palladino; Laura Peccini; Nicola Principi
Journal:  Front Pharmacol       Date:  2019-08-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.